Opiate receptor avidity (unoccupied receptor density / the receptor dissoci
ation constant), was measured in four animals with unilateral parkinsonian
symptoms following MPTP ( 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) inf
usions into the internal carotid of one side, and nine normal controls with
positron emission tomography (PET) and 6-deoxy-6-beta-[F-18] fluoronaltrex
one (cyclofoxy, CF), a mu- and kappa-opiate receptor antagonist. PET studie
s of 6-[F-18] -L-fluoro-L-3,4-dihydroxyphenylalanine ([F-18]-DOPA) in these
parkinsonian animals, although documenting the primarily unilateral nature
of the lesion, also demonstrated a milder loss of dopaminergic on the side
opposite the infusion. Opiate receptor avidity was found to be reduced by
20-34% in the caudate, anterior putamen, thalamus, and amygdala of these pr
imarily unilaterally MPTP-exposed animals, bilaterally with no statisticall
y significant differences between the two sides. The affected regions are t
he same as those previously demonstrated to have a 30-35% loss in clinicall
y recovered bilaterally MPTP-lesioned animals. These findings confirm that
the opiate pathway can change in response to modest decreases in basal gang
lia dopamine innervation. Thus, opiate pathway adaptation is likely to cont
ribute to the dynamic changes in basal ganglia circuits that forestall the
initial clinical manifestations of Parkinson's disease. In addition, opiate
pathway(s) may contribute to the treatment responsiveness and progression
of the disease either directly through effects on basal ganglia function or
indirectly through effects on basal ganglia plasticity. Synapse 33:282-288
, 1999. (C) 1999 Wiley-Liss, Inc.